Clinical trials: Knee OA
Osteoarthritis of the Knee, Type 2 Diabetes Mellitus
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
The purpose of this study was to compare the effects of FX006 and Triamcinolone Acetonide Injectable Suspension, United States Pharmacopeia (USP) (referred to as TCA IR in the protocol) on blood glucose (BG) in patients with…
- Trial name
- NCT02762370
- Testing
- FX006 32 mg, TCA IR 40 mg
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Pain
A Study to Characterize Diclofenac's Plasma and Knee Exposure After Application of Diclofenac Gel to the Knee of Subjects With Osteoarthritis That Have a Scheduled Arthroplasty
The purpose of this study is to evaluate the exposure of diclofenac in the plasma and in the knee joint following topical administration of DDEA gel 4 gram (g) applied twice daily for 7 days.
- Trial name
- NCT03497039
- Testing
- Diclofenac Diethylamine (DDEA) gel
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Osteoarthritis, Knee
Efficacy and Safety of G001 in Patients With Osteoarthritis (OA) of the Knee
Phase 2 multicenter, double-blind, randomized, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, and local tolerability of G001 topical gel compared to matching Vehicle topical gel in patients with…
- Trial name
- NCT05007808
- Testing
- G001 Topical Gel, Vehicle
- Where
- 10 sites in Canada
- Volunteers
- 210 people
- Sponsor
- BUZZZ Pharmaceuticals Limited
Gonarthrosis, Knee Osteoarthritis
Evaluation of Intra-articular Injection of Autologous Protein Solution ("APS(TM)") for the Treatment of Osteoarthritis (OA)
This prospective single-center study will evaluate the safety and tolerability of a single dose of "APS(TM)" treated patients with OA of the knee who have failed conservative OA therapy.
- Conditions
- Gonarthrosis, Knee Osteoarthritis, Osteoarthritis
- Trial name
- NCT01773226
- Testing
- Autologous Protein Solution "APS(TM)"
- Where
- Netherlands
- Volunteers
- 11 people
- Sponsor
- Zimmer Biomet
Osteoarthritis
Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly
The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).
- Trial name
- NCT00324038
- Testing
- Buprenorphine, Codeine paracetamol
- Where
- United Kingdom
- Volunteers
- 219 people
- Sponsor
- Napp Pharmaceuticals Limited
Osteoarthritis of the Knee
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
The objectives of this study were to characterize the local extent and duration of exposure of TA from FX006 and TCA IR, characterize the systemic PK of FX006 and TCA IR, and assess the safety and general tolerability of a single…
- Trial name
- NCT02637323
- Testing
- FX006 32 mg, TCA IR 40
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Knee Osteoarthritis
A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)
The study was established to show safety and efficacy of canakinumab and LNA043 in patients with knee osteoarthritis (OA).
- Trial name
- NCT04814368
- Testing
- canakinumab, LNA043
- Where
- 11 sites in United States, Czechia and 4 more
- Volunteers
- 23 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis of the Knee
Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
The purpose of this study was to characterize the local duration of exposure of TCA for 2 doses of FX006 relative to 40 mg of TCA IR in patients with OA of the knee.
- Trial name
- NCT02003365
- Testing
- FX006 10 mg, FX006 40 mg, TCA IR 40 mg
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Osteoarthritis, Knee
Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)
This study will evaluate the efficacy and safety of diclofenac DDEA 2.32 % in patient suffering from knee osteoarthritis (OA).
- Trial name
- NCT01967550
- Testing
- diclofenac diethylamine, DDEA 2.32% gel
- Where
- 5 sites in Germany
- Volunteers
- 304 people
- Sponsor
- Novartis
Osteoarthritis of the Knee
Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain
Phase 3 randomized, double-blind, placebo- and active comparator-controlled study of TLC599.
- Trial name
- EXCELLENCE (NCT04123561)
- Testing
- TLC599, DSP, Normal Saline
- Where
- 46 sites in United States, Australia
- Volunteers
- 504 people
- Sponsor
- Taiwan Liposome Company
Osteoarthritis
Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA
The purpose of this study is to demonstrate non-inferiority of three weekly intra-articular injections of SUPARTZ to three weekly intra-articular injections of Euflexxa for the relief of knee OA.
- Trial name
- NCT02110238
- Testing
- Supartz, Euflexxa
- Where
- United States
- Volunteers
- 421 people
- Sponsor
- Bioventus LLC
Osteoarthritis, Knee
Osteoarthritis Knee Pain Relief Study of 0.25% 920-CGS-200
This is a study of an over-the-counter, capsaicin-based (0.25%) topical analgesic for management of osteoarthritis knee pain meeting the US Food and Drug Administration's (FDAs) Tentative Final Monograph (TFM) guidance for…
- Trial name
- NCT03124407
- Testing
- Capsaicin Topical Solution, Drug product vehicle
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Propella Therapeutics
Pain, Inflammatory
A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)
This study is the first administration of GSK3858279 in humans and will be conducted in two parts: Part A will consist of a single ascending dose escalation design to evaluate safety, tolerability, PK, TE and immunogenicity of…
- Trial name
- NCT03485365
- Testing
- GSK3858279 IV, GSK3858279 SC
- Where
- 5 sites in Germany, Poland and 1 more
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoarthritis, Knee
Assess the Blood-Oxygen-Level-Dependent (BOLD) Signal Changes in the Brain by Paracetamol as Measured by Functional Magnetic Resonance Imaging (fMRI) in Subjects With Osteoarthritis (OA)
Blood-Oxygen-Level-Dependent (BOLD) responses to painful mechanical stimulation of the OA knee following treatment with four consecutive doses (at 8 hour intervals) on giving sustained released paracetamol treatment or placebo…
- Trial name
- NCT01105936
- Testing
- Paracetamol
- Where
- Spain
- Volunteers
- 31 people
- Sponsor
- GlaxoSmithKline
Osteoarthritis of the Knee
Efficacy and Safety of Repeated Intraarticular Injections of Hyaluronic Acid in Patients With OA of the Knee
The main objective is the long-term comparison (3 years and 4 months) of the efficacy and safety of repeated intra-articular administration of hyaluronic acid in the treatment of osteoarthritis of the knee.
- Trial name
- NCT00669032
- Testing
- Hyaluronic acid
- Volunteers
- 446 people
- Sponsor
- Tedec-Meiji Farma, S.A.
Osteoarthritis of the Knee
Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients
This trial is a Phase IIa, Randomized, Double blinded, Placebo controlled, Dose finding Study to investigate the safety and efficacy of TLC599 in subjects with osteoarthritis of the knee.
- Trial name
- NCT03005873
- Testing
- TLC599 LD group, Normal Saline, TLC599 HD group
- Where
- 13 sites in Australia, Taiwan
- Volunteers
- 76 people
- Sponsor
- Taiwan Liposome Company
Osteoarthritis of the Knee
Efficacy and Safety Study of Glucosamine/Chondroitin Sulfate to Patients Treatment With Osteoarthrosis of the Knee
The purpose of this study is to assess the efficacy and safety of glucosamine and chondroitin sulfate association in the treatment of patients with osteoarthrosis of the knee.
- Trial name
- Artico (NCT00955552)
- Testing
- Glucosamine sulphate and chondroitin sulphate association, Cosamin DS® (Nutramax)
- Where
- 4 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Eurofarma Laboratorios S.A.
Bilateral Knee Osteoarthritis
Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA
This is a randomized, open-label, parallel group study to compare systemic exposure of triamcinolone acetonide following administration into both knees of either FX006 or TAcs.
- Trial name
- NCT03378076
- Testing
- FX006 32 mg, TAcs 40 mg
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Osteoarthritis of the Knee
Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee
This study is to validate the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) tool in mainland Chinese patients with osteoarthritis of the knee .
- Trial name
- NCT01430559
- Testing
- Meloxicam
- Where
- 25 sites in China
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Pain
A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain
To evaluate the efficacy of OROS Hydromorphone in reducing moderate to severe chronic pain in patients with Osteoarthritis (OA) Pain
- Trial name
- NCT00631319
- Testing
- OROS hydromorphone
- Volunteers
- 343 people
- Sponsor
- Mallinckrodt